Supplements for heart health
Compared by effect and evidence certainty. Cost is not currently assessed, and nothing here is sold to you.
Omega-3grade Bmoderate certainty— modest cardiovascular benefit; large recent trials were mixed Safety: serious — High-dose omega-3 with warfarin may increase bleeding risk.. Cost: not assessed. Evidence gaps: population bounds not reported.
Berberinegrade Bmoderate certainty— Meta-analysis of RCTs: berberine improved several cardiovascular risk factors — lowering total and LDL cholesterol, triglycerides, and blood pressure — versus control. It is a risk-factor signal, not a demonstrated reduction in cardiovascular events. Safety: moderate — Berberine also lowers glucose; combined with metformin it can compound hypoglycemia. Monitor with your clinician.. Cost: not assessed. Evidence gaps: no major structured gap flagged; review the claim limitations.
Magnesiumgrade Bmoderate certainty— Meta-analysis of 38 RCTs (2709 participants): magnesium supplementation modestly lowered blood pressure — systolic by about 2.8 mm Hg and diastolic by about 2.0 mm Hg versus control. A small but consistent blood-pressure effect; not shown to reduce cardiovascular events directly. Safety: minor — Generally fine with an SSRI; space about 2 hours apart.. Cost: not assessed. Evidence gaps: no major structured gap flagged; review the claim limitations.
Zincgrade Bmoderate certainty— GRADE-assessed meta-analysis of 75 studies: zinc supplementation significantly lowered several cardiometabolic risk markers — triglycerides, total cholesterol, fasting blood glucose, HbA1c, insulin resistance (HOMA-IR), and inflammatory markers (CRP, IL-6, TNF-alpha). A broad risk-factor signal across many biomarkers, not a demonstrated reduction in cardiovascular events. Safety: no modeled interaction found; coverage unknown, not proven safe. Cost: not assessed. Evidence gaps: no major structured gap flagged; review the claim limitations.
Vitamin Cgrade Clow certainty— Systematic review: overall there is limited evidence that vitamin C supplementation improves cardiovascular biomarkers in the general population. Subgroups — people with low baseline vitamin C status or higher cardiovascular risk — may be more responsive, but this is a tentative, subgroup-level signal. Safety: no modeled interaction found; coverage unknown, not proven safe. Cost: not assessed. Evidence gaps: certainty or evidence strength remains limited.
CoQ10grade Dvery-low certainty— UK HTA review of 26 RCTs (n=2250) in heart failure: mortality RR 0.68 but CI crosses null (0.45-1.03); authors say stronger evidence is needed before this could inform prescribing. Safety: no modeled interaction found; coverage unknown, not proven safe. Cost: not assessed. Evidence gaps: certainty or evidence strength remains limited.
Vitamin Dstudied, no effectmoderate certainty— Meta-analysis of RCTs: vitamin D supplementation was NOT associated with a lower risk of cardiovascular events versus no supplementation. The authors explicitly state the findings do not support routine vitamin D supplementation for cardiovascular prevention. Safety: minor — Magnesium is a cofactor in vitamin D metabolism; the two are complementary.. Cost: not assessed. Evidence gaps: certainty or evidence strength remains limited.
Creatinestudied, no effectlow certainty— Meta-analysis of 8 RCTs: creatine supplementation showed no statistically significant effect on total cholesterol, LDL, HDL, or triglycerides versus control. Certainty of evidence was rated very low to low due to methodological limitations in the included trials. Safety: no modeled interaction found; coverage unknown, not proven safe. Cost: not assessed. Evidence gaps: certainty or evidence strength remains limited.